Drug Combination Details
| General Information of the Combination (ID: C72463) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Clofarabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Peritoneal cancer
[ICD-11: 2C51]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PSG1 | Molecule Info | |||
| In-vitro Model | MeT-5A | CVCL_3749 | Healthy | Homo sapiens | ||
| MSTO-211H | CVCL_1430 | Pleural biphasic mesothelioma | Homo sapiens | |||
| Experimental
Result(s) |
The synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GABPA | Molecule Info | |||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MSTO-211H | CVCL_1430 | Pleural biphasic mesothelioma | Homo sapiens | ||
| Experimental
Result(s) |
Clofarabine and resveratrol cooperatively exerted cytotoxic effects in MSTO-211H cells. The observed synergism was mediated, at least in part, through suppression of the Nrf2 and PI3K/Akt signalings. | |||||
